patent.fyi
Applications  /  US 2026/0356830
United States Patent Application Publication

US 2026/0356830 A1

Published
Nov 12, 2026
Filed
Aug 2, 2023
Earliest date on the face
Aug 3, 2022
Classification
C07D 471/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Ethylsulfanyl group at R1

What ifWhat if R1 were an ethylsulfanyl group attached to the RET-binding ring through sulfur?
Claim language“—OCH3, —OCH2CH3”

The ring–S–CH2CH3 connection projects an ethyl group from the same attachment site. The larger sulfur atom changes the bond geometry and polarizability at the entrance to the pocket.

1.2Ethynyl group at A

What ifWhat if A were a terminal ethynyl group that projects into a narrow pocket on RET?
Claim language“aryl, or heteroaryl”

A direct bond joins the binding scaffold to the first carbon of —C≡CH. The triple bond gives the substituent a linear profile that places the terminal carbon along the attachment axis.

1.5Recruitment to an autophagic membrane

What ifWhat if the RET-binding group were tethered to a ligand for a protein on an autophagic membrane?
Claim language“a moiety that is capable of binding a E3 ligase”

One end binds the cytosolic kinase domain of RET, and the other binds lipidated microtubule-associated protein 1 light chain 3 on a forming autophagosome. The tether brings RET-containing membrane cargo to the autophagosome for delivery to a lysosome, where hydrolases digest the cargo.

1.6Sulfide junction at L1

What ifWhat if L1 joined the RET-binding scaffold and the spacer through a sulfide junction?
Claim language“—O—, or —NH—”

A divalent sulfur atom joins a carbon on the binding scaffold to a carbon at the spacer terminus. The two carbon–sulfur bonds provide a one-atom junction with longer bonds than a carbon–oxygen junction.

1.10Rigid alkyne spacer at Y1

What ifWhat if Y1 used a two-carbon ethynylene unit to set the direction of the adjoining linker segments?
Claim language“4- to 12-membered heterocycloalkyl”

The internal —C≡C— unit places its adjoining bonds on a common axis. The triple bond fixes the bond angles at both spacer carbons and gives this part of the linker a fixed end-to-end distance.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reversible RET depletion in organoids

Use a bifunctional RET degrader as a research reagent in human thyroid epithelial organoids embedded in an extracellular matrix gel. Add the degrader to the culture medium to recruit an E3 ubiquitin ligase to RET during a defined exposure window. Exchange the medium and measure total RET and phosphorylated ERK at successive time points to track protein recovery and downstream signaling.

Component substitution

Triazole junction in the linker

Replace an amide junction in L2 with a 1,4-disubstituted 1,2,3-triazole while retaining the RET-binding and E3 ligase-binding ends. Install a terminal alkyne on the RET-side intermediate and an azide on the ligase-side intermediate, then couple them by copper-catalyzed azide–alkyne cycloaddition. The triazole fixes the relative directions of the two linker segments and removes the amide NH hydrogen-bond donor.

Covalent recruitment of an E3 ligase

Use an acrylamide-bearing DCAF16 recruiter as moiety B and attach L2 through a separate handle on the recruiter scaffold. The acrylamide reacts with a cysteine on DCAF16, the substrate receptor of a CUL4 ubiquitin ligase complex. Measure DCAF16 engagement and total RET abundance in the same cell system because covalent engagement and RET access to the recruited complex are separate requirements.

Parameter or scale variation

Matched linker series with four lengths

Build four conjugates with the same RET-binding head, L1, and ligase recruiter, and set a single linear segment of L2 to 2, 4, 6, or 8 methylene groups. Keep the terminal junctions and their orientation fixed across the series. Measure total RET after 6 and 24 hours at 10, 100, and 1000 nanomolar to compare how spacer length affects the timing and extent of depletion.

Combination with existing systems

Continuous perfusion with timed degrader exposure

Integrate the RET degrader with a glass microfluidic cell culture chamber supplied by separate reservoirs for vehicle medium and degrader medium. Connect the reservoirs through a switching valve to a shared inlet and use the same flow rate during dosing and washout. Switch the inlet to degrader medium for a timed pulse, return it to vehicle medium, and collect cells from replicate chambers at defined intervals for total RET measurement.

Automated or data-driven variant

Closed-loop selection of linker structures

Store candidate structures as combinations of a RET-binding head, an E3 ligase recruiter, and linker fragments with defined attachment points. Use a liquid handler to dispense prepared conjugates into cell assay plates and record total RET and viability at each concentration. Fit a Gaussian process model to the measured depletion data and use predicted depletion and model uncertainty to rank untested structures within a viability threshold. Feed each new batch of measurements back into the model before selecting the next batch.

Specific version of a part

Methoxy substitution on phenyl

A phenyl group at A carries methoxy at the carbon opposite its attachment to the scaffold. The oxygen links the ring to a terminal methyl group and provides a hydrogen-bond acceptor.

Piperidine linker with terminal amide

A single methylene connects the upstream attachment point to the nitrogen of a piperidine ring. Carbon 4 of the ring connects directly to a carbonyl, and the terminal segment begins with —CH2NH—, whose nitrogen forms an amide with a carboxyl-bearing ligase ligand.

Amide linker with two oxyethylene units

The linker runs from the upstream attachment point through —C(O)NH—CH2CH2—O—CH2CH2—O—. The terminal oxygen bonds directly to the downstream binding group, with Y2 set to a bond.

Symmetric amide spacer at Y2

Y2 runs from the upstream attachment point to the downstream attachment point as —CH2CH2—C(O)NH—CH2CH2—. Two methylene groups flank each side of the central amide, which presents a carbonyl acceptor and an N–H donor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2019/0112307 A1
Published
Apr 18, 2019
Filed
Apr 21, 2017
Class
C07D 471/04
Document BUS 2022/0218831 A1
Published
Jul 14, 2022
Filed
Apr 30, 2020
Class
A61K 47/556
Document CUS 2018/0086703 A1
Published
Mar 29, 2018
Filed
Sep 11, 2017
Class
C07D 209/44
Claim 1
Document A
Document B
1.1R1 is —OCH3, —OCH2CH3, —OCF3, —OCH2CH2OH, —OCH2CH2F, halogen, or 1-methyl-pyrazol-4-yl
R3 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, hydroxy, amino, and halo;
B · US 2022/0218831 A1 · claim 2
1.2A is independently H, OH, C1-C6 alkyl, C3-C8 cycloalkyl, aryl, or heteroaryl
R5 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkoxy, C5-C1 heteroaryl, C6-C10 aryl, C3-C6 cycloalkyl, and C3-C6 heterocycloalkyl; wherein C5-C1 heteroaryl and C6-C1 aryl are optionally substituted with C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 alkylamine;
B · US 2022/0218831 A1 · claim 2
1.3wherein the alkyl, cycloalkyl, aryl or heteroaryl is optionally substituted with one or more R2
Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
A · US 2019/0112307 A1 · ¶ 525
1.4wherein R2 is independently halogen, OH, C1-C3 alkyl, or C1-C3 alkoxy
each R2 is independently (C1-C4) alkyl, (C1-C4) haloalkyl, (C1-C4) alkoxy, (C1-C4) haloalkoxy, halogen, OH, or NH2;
A · US 2019/0112307 A1 · ¶ 72
1.5B is a moiety that is capable of binding a E3 ligase
In particular, the present application is directed to compounds which contain a moiety, e.g., a small molecule moiety (i.e., having a molecular weight of below 2,000), 1,000, 500, or 200 Daltons), such as a thalidomide-like moiety, which is capable of binding to an E3 ubiquitin ligase, such as cereblon, and a ligand that is capable of binding to a target protein, in such a way that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and/or
A · US 2019/0112307 A1 · ¶ 46
A compound of Formula X: or a pharmaceutically acceptable salt thereof; wherein: the targeting ligand is a ligand capable of binding to a targeted protein; the linker is a group that covalently binds to the targeting ligand and the degron; the degron is capable of binding to a ubiquitin ligase; and n is 1-3.
B · US 2022/0218831 A1 · claim 1
1.6L1 is independently a bond, —C1-C3 alkylenyl-, —NHCO—, —CONH—, —O—, or —NH—
R2 is covalently bonded to the linker and is selected from the group consisting of a direct bond, —NH—, —NCH3—, —O—, —S—, and —CH2—;
B · US 2022/0218831 A1 · claim 2
1.7L2 is independently —(CH2)p-(4- to 12-heterocycloalkyl)-Y1—C(O)—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-C(O)—Y1-Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-C(O)—Y1—C(O)—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-Y1-Y2—, —(OCH2CH2)p-(4- to 12-heterocycloalkyl)-Y2—, —(CH2OCH2C(O))p-(4- to 12-heterocycloalkyl)-Y2—, —(CH2OCH2C(O)NH)p—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-Y1—(CH2CH2O)p—C(O)—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-Y1—(CH2CH2O)p—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-Y1—(OCH2CH2)p—Y2—, —(CH2)p-(4- to 12-heterocycloalkyl)-Y1—(OCH2CH2)p—C(O)—(OCH2CH2)p—Y2, —(CH2OCH2)p-(heteroaryl)-Y2—, —NHC(O)-(4- to 12-heterocycloalkyl)-Y1—C(O)—Y2—, —NHC(O)—(CH2)p-(4- to 12-heterocycloalkyl)-Y1—C(O)—Y2—, —NHC(O)—(CH2)p-(4- to 12-heterocycloalkyl)-Y2—, —C(O)NH—Y1-Y2—
1.8—(CH2)p—NH—Y1-Y2—
1.9—C(O)NH—(CH2CH2O)p—Y2—, —C(O)—(CH2CH2O)p—Y2—, —(CH2OCH2)p—NR3C(O)—(CH2CH2O)p—Y2—, —(CH2)p—NR3C(O)—(CH2CH2O)p—Y2—, —(CH2OCH2CH2)p-(4- to 12-heterocycloalkyl)-Y1—C(O)—(CH2CH2O)p—Y2—, or —(CH2OCH2)p—C(O)NH—(CH2CH2O)p—Y2—
1.10wherein R3 is —H or —C1-C3 alkyl, Y1 is independently a bond, —C1-8 alkylenyl, 4- to 12-membered heterocycloalkyl, or —C3-C10 cycloalkyl
1.11Y2 is independently a bond, —C1-C3 alkyl-, —(CH2)m—O—, —O—(CH2)m-(4- to 6-membered heterocycloalkyl), —(CH2)m—O—(CH2)m—NH—, —(CH2)m—NH—, —(CH2)m—NHC(O)—(CH2)mO—, —(CH2)m—C(O)NH—(CH2)m—, —(CH2)m—C3-C10 cycloalkyl-, —(CH2)m-aryl, —(CH2)m-heteroaryl-, —(CH2)m-(4- to 6-membered heterocycloalkyl)-, —(CH2)m-(4- to 6-membered heterocycloalkyl)-C(O)—, —(CH2)m-(4- to 6-membered heterocycloalkyl)-C(O)—(CH2)m—, —(CH2)m-(4- to 6-membered heterocycloalkyl)-C(O)—(CH2)m—O—, —(CH2)m—C3-C10 cycloalkyl-C(O)NH—, or —(CH2)m-(4- to 6-membered heterocycloalkyl)-O—, X1 is CH or N
Z1 is absent, C(O), (CH2)jC(O)NH, CH2, O, NH, or NR19; each R19 is independently C1-C3 alkyl; j is 1, 2, or 3; and Q is absent or NHC(O)CH2, wherein the Linker is covalently bonded to the Degron via the next to Q, and covalently bonded to the Targeting Ligand via the next to Z1.
A · US 2019/0112307 A1 · claim 23
1.12X2 is CH or N m is independently at each occurrence an integer from 0 to 16 n is an integer from 0 to 2 p is an integer from 0 to 3.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Alternative strategies to inhibit cyclin-dependent kinases, such as CDK8, are needed.
A · US 2019/0112307 A1 · ¶ 7
The present application relates to novel bifunctional compounds, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
A · US 2019/0112307 A1 · ¶ 8
Therefore, there remains a need for structurally diverse inhibitors of Aurora kinase activity, particularly ones that are potent and/or selective inhibitors of AURKA and/or AURKB.
B · US 2022/0218831 A1 · ¶ 3
Targeting these proteins for degradation provides numerous advantages over merely inhibiting protein function (e.g., kinase activity).
B · US 2022/0218831 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0356830 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356830/, SHA-256 5bca05a0ef617d960242e56de24b2bedee4b80be1ac5f37fe4ab8d52e64cc248
First published
Permanent addresshttps://patent.fyi/US20260356830/
Content fingerprint (SHA-256)5bca05a0ef617d960242e56de24b2bedee4b80be1ac5f37fe4ab8d52e64cc248
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi